Bibliography
- MOSMANN TR, COFFMAN RL: TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol. (1989) 7:145-173.
- ROMAGNANI S: The TH1/TH2 paradigm. Immunol. Today (1997) 18:263-266.
- LIEW FY: TH1 and TH2 cells: a historical perspective. Nat. Rev. Immunol. (2002) 2:55-60.
- DUMONT FJ: Modulation of TH1 and TH2 responses for immunotherapy. Expert Opin. Ther. Patents (2002) 12:341-367.
- MOSS RB, MOLL T, EL-KALAY M et al.: TH1/TH2 cells in inflammatory disease states: therapeutic implications. Expert Opin. Biol. Ther. (2004) 3:1887-1896.
- KUCHROO VK, UMETSU DT, DEKRUYFF RH, FREEMAN GJ: The TIM gene family: emerging roles in immunity and disease. Nat. Rev. Immunol. (2003) 3:454-462.
- MEYERS JH, SABATOS CA, CHAKRAVARTI S, KUCHROO VK: The TIM gene family regulates autoimmune and allergic diseases. Trends Mol. Med. (2005) 11:362-369.
- ICHIMURA T, BONVENTRE JV, BAILLY V et al.: Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is upregulated in renal cells after injury. J. Biol. Chem. (1998) 273:4135-4142.
- FEIGELSTOCK D, THOMPSON P, MATTOO P, ZHANG Y, KAPLAN GG: The human homolog of HAVcr-1 codes for a hepatitis A virus cellular receptor. J. Virol. (1998) 72:6621-6628.
- MCINTIRE JJ, UMETSU SE, AKBARI O et al.: Identification of Tapr (an airway hyper-reactivity regulatory locus) and the linked Tim gene family. Nat. Immunol. (2001) 2:1109-1116.
- KHADEMI M, ILLES Z, GIELEN AW et al.: T cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human TH1 and TH2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J. Immunol. (2004) 172:7169-7176.
- DE SOUZA AJ, ORISS TB, O’MALLEY KJ, RAY A, KANE LP: T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation. Proc. Natl Acad. Sci. USA (2005) 102:17113-17118.
- UMETSU SE, LEE WL, MCINTIRE JJ et al.: TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat. Immunol. (2005) 6:447-454.
- CHAE SC, SONG JH, HEO JC et al.: Molecular variations in the promoter and coding regions of human Tim-1 gene and their association in Koreans with asthma. Hum. Immunol. (2003) 64:1177-1182.
- MCINTIRE JJ, UMETSU DT, DEKRUYFF RH: TIM-1, a novel allergy and asthma susceptibility gene. Springer Semin. Immunopathol. (2004) 25:335-348.
- CHAE SC, PARK YR, SONG JH et al.: The polymorphisms of Tim-1 promoter region are associated with rheumatoid arthritis in a Korean population. Immunogenetics (2005) 56:696-701.
- CHAKRAVARTI S, SABATOS CA, XIAO S et al.: Tim-2 regulates T helper Type 2 responses and autoimmunity. J. Exp. Med. (2005) 202:437-444.
- KUMANOGOH A, MARUKAWA S, SUZUKI K et al.: Class IV semaphorin Sema4A enhances T cell activation and interacts with Tim-2. Nature (2002) 419:629-633.
- MONNEY L, SABATOS CA, GAGLIA JL et al.: TH1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature (2002) 415:536-541.
- SANCHEZ-FUEYO A, TIAN J, PICARELLA D et al.: Tim-3 inhibits T helper Type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat. Immunol. (2003) 4:1093-1101.
- SABATOS CA, CHAKRAVARTI S, CHA E et al.: Interaction of Tim-3 and Tim-3 ligand regulates T helper Type 1 responses and induction of peripheral tolerance. Nat. Immunol. (2003) 4:1102-1110.
- ZHU C, ANDERSON AC, SCHUBART A et al.: The Tim-3 ligand galectin-9 negatively regulates T helper Type 1 immunity. Nat. Immunol. (2005) 6:1245-1252.
- CHAE SC, PARK YR, LEE YC, LEE JH, CHUNG HT: The association of TIM-3 gene polymorphism with atopic disease in Korean population. Hum. Immunol. (2004) 65:1427-1431.
- CHAE SC, PARK YR, SHIM SC, YOON KS, CHUNG HT: The polymorphisms of TH1 cell surface gene Tim-3 are associated in a Korean population with rheumatoid arthritis. Immunol. Lett. (2004) 95:91-95.
- MEYERS JH, CHAKRAVARTI S, SCHLESINGER D et al.: TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat. Immunol. (2005) 6:455-464.
- ENCINAS JA, JANSSEN EM, WEINER DB et al.: Anti-T cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma. J. Allergy Clin. Immunol. (2005) 116:1343-1349.
- GENG H, ZHANG GM, LI D et al.: Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. J. Immunol. (2006) 176:1411-1420.
- HARRINGTON LE, HATTON RD, MANGAN PR et al.: IL-17- producing CD4+ effector T cells develop via a lineage distinct from the T helper Type 1 and 2 lineages. Nat. Immunol. (2005) 6:1123-1132.
- PARK H, LI Z, YANG XO et al.: A distinct lineage of CD4 T cells regulates tissue inflammation by producing IL-17. Nat. Immunol. (2005) 6:1133-1141.
- DONG C: Diversification of T helper-cell lineages: finding the family root of IL-17-producing cells. Nat. Rev. Immunol. (2006) 6:329-334.
- MESTAS J, HUGHES CC: Of mice and not men: differences between mouse and human immunology. J. Immunol. (2004) 172:2731-2738.
- MESRI M, SMITHSON G, GHATPANDE A et al.: Inhibition of in vitro and in vivo T cell responses by recombinant human Tim-1 extracellular domain proteins. Int. Immunol. (2006) 18:473-484.
- ICHIMURA T, HUNG CC, YANG SA, STEVENS JL, BONVENTRE JV: Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am. J. Physiol. Renal Physiol (2004) 286:F552-F563.
- GIELEN AW, LOBELL A, LIDMAN O et al.: Expression of T cell immunoglobulin- and mucin-domain-containing molecules-1 and -3 (TIM-1 and -3) in the rat nervous and immune systems. J. Neuroimmunol. (2005) 164:93-104.
- CHEN TT, LI L, CHUNG DH et al.: TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J. Exp. Med. (2005) 202:955-965.
Patents
- UNIV. LELAND STANFORD JUNIOR: WO03002722 (2003).
- BRIGHAM & WOMENS HOSPITAL; DANA FARBER CANCER INST. INC. WO03063792 (2003).
- ABGENIX INC.: WO2004084823 (2004).
- TELOS PHARMACEUTICALS INC.: WO2005097211 (2005).
- WO2005090573
- WO2005033144